Western blotting further displayed that AS-IV treatment downregulated the levels of DN-affected proteins MMP-9, MPO, IL-1β, IL-6, and TNF-α.<h4>Conclusions</h4>Overall, combining the network pharmacology and experimental validation offers a precise elucidation of the molecular mechanism by which AS-IV treats DN. The gene discussed is IL1B; the disease is liver dysplastic nodule.